Mwandishi:
Mhariri:
Imeboreshwa:
ULY CLINIC
ULY CLINIC
2 Julai 2026, 10:55:21
Management of mild COVID-19
Mild covid 19 disease
There is no single curative (“magic-bullet”) therapy for COVID-19. The disease is a multi-phase viral-inflammatory syndrome, therefore treatment requires:
Stage-specific therapy
Organ support
Thrombosis prevention
Careful monitoring for deterioration
Management differs according to severity:
Mild disease (Home care)
Moderate disease (Pneumonia)
Severe disease (Severe pneumonia)
Critical disease
A. MILD COVID-19 DISEASE (HOME CARE)
Clinical definition
Symptomatic patient without hypoxia or pneumonia
Goals of Care
Prevent progression
Reduce transmission
Provide symptom relief
Educate patient on danger signs
Discharge & isolation instructions
Patient must:
Self-isolate
Wear mask around others
Use separate utensils and sleeping area
Maintain hydration and nutrition
Monitor symptoms daily
Pharmacologic treatment
Supportive supplements
Medication | Dose | Duration | Purpose |
Vitamin C | 500 mg OD | 2 weeks | Immune modulation |
Zinc sulphate | 40 mg OD | 2 weeks | Antiviral support |
Vitamin D3 | 1000–5000 IU OD | 2 weeks | Immune regulation |
Symptomatic treatment
Antipyretics (Paracetamol)
Antihistamine (if URTI symptoms)
Cough syrup if needed
Conditional treatments
Only if clinically suspected:
Condition | Treatment |
Bacterial infection | Antibiotics per guideline |
Malaria positive | Antimalarial regimen |
Other infections | Treat accordingly |
Antibiotics are NOT routinely indicated
Patient education — Danger signs
Return immediately if:
Difficulty breathing
Chest tightness
Persistent fever
Confusion
Reduced consciousness
Remarks
Early supplements may support immune response
Community awareness reduces transmission
Zinc deficiency associated with increased infection risk
CORE PRINCIPLE OF COVID-19 MANAGEMENT
Mild → symptomatic care
Moderate → anti-inflammatory therapy
Severe → oxygen + steroids + anticoagulation
Critical → organ support + ICU care
Imeandikwa:
24 Machi 2021, 17:49:23
